key: cord-0731425-wxg6p6r3
authors: Ding, Defang; Zhu, Caisong; Yao, Weiwu
title: A cured patient with 2019-nCoV pneumonia
date: 2020-03-20
journal: Am J Med
DOI: 10.1016/j.amjmed.2020.02.023
sha: cd7c9b90c39c64262d651b6e4f88750afc6db0a8
doc_id: 731425
cord_uid: wxg6p6r3

nan

On examination, she was conscious with a body temperature of 38.3℃ and vital signs were stable. Small moist rales were heard in both lungs. Laboratory tests of the blood revealed 4.49×10 6 white blood cells per μL, with increased proportion of neutrophils (78.1%) and decreased proportion of lymphocytes (18.0%). C-reactive protein elevated to73.4 mg/L. Chest 

The patient received moxifloxacin (400 mg once daily intravenously for 8 days then switch to oral treatment), oseltamivir (75 mg twice daily orally for 5 days) and supportive therapy. The patient recovered with improved symptoms, and on treatment evaluation of chest CT obtained 7 days later showed decreased extent and intensity of the lesions, although irregular consolidation (asterisk) emerged in the subpleural regions of the right lower lung ( figure 1B) .

The patient was discharged after her body temperature returned to normal for at least 3 days and two consecutive negative tests for 2019-nCoV nucleic acid. A repeat chest CT performed 10 days later showed significantly improved lesions ( figure 1C) . Currently, the patient is still under follow-up with favorable condition. 

A Novel Coronavirus from Patients with Pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan